Ignite Creation Date:
2024-05-06 @ 7:33 PM
Last Modification Date:
2024-10-26 @ 3:09 PM
Study NCT ID:
NCT06056921
Status:
RECRUITING
Last Update Posted:
2023-09-28
First Post:
2023-08-18
Brief Title:
Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease
Sponsor:
Chongqing Precision Biotech Co Ltd
Organization:
Chongqing Precision Biotech Co Ltd
Study Overview
Official Title:
Clinical Study of CD19 Targeting Chimeric Antigen Receptor T Lymphocytes CAR-T in the Treatment of Refractory Autoimmune Diseases
Status:
RECRUITING
Status Verified Date:
2023-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a single arm study to evaluate the efficacy and safety of CD19 targeted CAR-T cells therapy for patients with Refractory Autoimmune Disease
Detailed Description:
the CD19 targeted CAR-T cell therapies have gained significant results in patients with relapsed and refractory B-cell Leukemia and Lymphoma Otherwise some studies have shown that the use of CD19-targeted CAR-T therapy in refractory SLE can improve the autoimmune symptoms of patients and at the same time immunosuppressants and hormones can be stopped to maintain long-term autoimmune indicators normalTo verify the safety and efficacy the investigators launch such a clinical trial using CD19 targeted CAR-T cells for patients with Refractory Autoimmune Disease
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None